Business Context and Reporting Period
This Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on August 19, 2026. The report details a significant regulatory milestone: the U.S. Food and Drug Administration (FDA) granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401. The drug is indicated for adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa).
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Clinical Data
The primary material change is the regulatory approval of GENGLYCOS based on the Phase 3 GlucoGene study. Key clinical data points include:
- Study Design: 48-week randomized, double-blind, placebo-controlled trial.
- Participants: 46 participants aged eight years and older (20 treated with DTX401, 24 placebo).
- Efficacy: The treated group showed a statistically significant reduction in cornstarch requirements (p<0.001).
- Post-Trial: Participants crossed over to the alternate treatment at Week 48, with follow-up analyses at Week 96 and Week 144.
Guidance, Outlook, and Post-Marketing Requirements
As a condition of accelerated approval, Ultragenyx has committed to specific post-marketing study requirements:
- Study Scope: Provide two years of safety and efficacy data from open-label commercial treatment.
- Population: 50 treated patients and 20 control patients (those with anti-AAV8 antibodies ineligible for treatment).
- Program: Data will be collected through the existing GSDIa Disease Monitoring Program (DMP).
- Duration: The DMP will evaluate both previously treated clinical trial participants and new commercial patients for a total of 10 years.
- Objectives: Support data on reduced cornstarch burden, fasting tolerance, and other measures in a commercial setting.
Investor Verification Checklist
- Verify the specific terms of the accelerated approval and any potential withdrawal conditions if confirmatory trials fail.
- Confirm the timeline and enrollment progress for the required post-marketing study of 50 treated and 20 control patients.
- Assess the commercial launch strategy and pricing for GENGLYCOS following FDA approval.
- Review the long-term safety profile of the gene therapy as data accumulates over the 10-year DMP period.